JP2019511533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511533A5 JP2019511533A5 JP2018553428A JP2018553428A JP2019511533A5 JP 2019511533 A5 JP2019511533 A5 JP 2019511533A5 JP 2018553428 A JP2018553428 A JP 2018553428A JP 2018553428 A JP2018553428 A JP 2018553428A JP 2019511533 A5 JP2019511533 A5 JP 2019511533A5
- Authority
- JP
- Japan
- Prior art keywords
- dengue
- chimera
- den
- pharmaceutical composition
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012310 Dengue fever Diseases 0.000 claims 47
- 208000025729 dengue disease Diseases 0.000 claims 47
- 208000001490 Dengue Diseases 0.000 claims 46
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 241000710815 Dengue virus 2 Species 0.000 claims 18
- 235000001014 amino acid Nutrition 0.000 claims 18
- 230000002238 attenuated effect Effects 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 241000725619 Dengue virus Species 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 10
- 230000003612 virological effect Effects 0.000 claims 10
- 101800001030 Non-structural protein 2A Proteins 0.000 claims 8
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 101710172711 Structural protein Proteins 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000000087 stabilizing effect Effects 0.000 claims 4
- 229940031351 tetravalent vaccine Drugs 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- 229920001992 poloxamer 407 Polymers 0.000 claims 3
- 229940044476 poloxamer 407 Drugs 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- 101710145006 Lysis protein Proteins 0.000 claims 2
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 2
- 101710144121 Non-structural protein 5 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 210000000234 capsid Anatomy 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022069423A JP2022089964A (ja) | 2016-04-13 | 2022-04-20 | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| JP2024044760A JP2024071463A (ja) | 2016-04-13 | 2024-03-21 | 小児及び若年成人のデングウイルスに対するワクチンの組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322167P | 2016-04-13 | 2016-04-13 | |
| US62/322,167 | 2016-04-13 | ||
| PCT/IB2017/052160 WO2017179017A1 (en) | 2016-04-13 | 2017-04-13 | Compositions and methods of vaccination against dengue virus in children and young adults |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069423A Division JP2022089964A (ja) | 2016-04-13 | 2022-04-20 | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019511533A JP2019511533A (ja) | 2019-04-25 |
| JP2019511533A5 true JP2019511533A5 (enExample) | 2020-05-14 |
Family
ID=58671740
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553428A Pending JP2019511533A (ja) | 2016-04-13 | 2017-04-13 | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| JP2022069423A Pending JP2022089964A (ja) | 2016-04-13 | 2022-04-20 | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| JP2024044760A Withdrawn JP2024071463A (ja) | 2016-04-13 | 2024-03-21 | 小児及び若年成人のデングウイルスに対するワクチンの組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069423A Pending JP2022089964A (ja) | 2016-04-13 | 2022-04-20 | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| JP2024044760A Withdrawn JP2024071463A (ja) | 2016-04-13 | 2024-03-21 | 小児及び若年成人のデングウイルスに対するワクチンの組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11007261B2 (enExample) |
| EP (1) | EP3442571A1 (enExample) |
| JP (3) | JP2019511533A (enExample) |
| KR (1) | KR102611235B1 (enExample) |
| CN (2) | CN120392993A (enExample) |
| AU (2) | AU2017250696A1 (enExample) |
| BR (1) | BR112018071087A2 (enExample) |
| CA (1) | CA3020484A1 (enExample) |
| CO (1) | CO2018011355A2 (enExample) |
| MX (1) | MX2018012459A (enExample) |
| MY (1) | MY192806A (enExample) |
| PH (1) | PH12018502175B1 (enExample) |
| SG (2) | SG10201913383RA (enExample) |
| WO (1) | WO2017179017A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102389908B1 (ko) | 2013-03-15 | 2022-04-26 | 다케다 백신즈 인코포레이티드 | 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법 |
| KR102611235B1 (ko) * | 2016-04-13 | 2023-12-08 | 다케다 백신즈 인코포레이티드 | 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법 |
| TW202309276A (zh) | 2016-08-03 | 2023-03-01 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
| CN111447947B (zh) * | 2017-12-07 | 2024-01-12 | 默沙东有限责任公司 | 登革病毒疫苗组合物的制剂 |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| ES2908304T3 (es) * | 2018-09-05 | 2022-04-28 | Takeda Vaccines Inc | Dosis unitaria de vacuna contra el dengue y administración de la misma |
| PH12022550261A1 (en) * | 2019-08-16 | 2023-06-26 | Takeda Vaccines Inc | Methods for preventing dengue and hepatitis a |
| WO2021174059A1 (en) | 2020-02-27 | 2021-09-02 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| EP3892737A1 (en) * | 2020-04-09 | 2021-10-13 | Takeda Vaccines, Inc. | Qualitative and quantitative determination of single virus haplotypes in complex samples |
| WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| US20250177511A1 (en) | 2022-02-15 | 2025-06-05 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| WO2024086681A1 (en) * | 2022-10-20 | 2024-04-25 | Takeda Vaccines, Inc. | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype |
| EP4612495A1 (en) * | 2022-11-02 | 2025-09-10 | Takeda Vaccines, Inc. | A method for determining the infectivity of a virus |
| EP4375381A1 (en) | 2022-11-18 | 2024-05-29 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| EP4626574A1 (en) | 2022-11-29 | 2025-10-08 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2338508T (pt) * | 2002-05-03 | 2018-05-16 | The Government Of The Us Secretary Department Of Health And Human Services | Vírus da dengue quimérico recombinante rden3/4delta30(me), rden2/4delta30(me) ou rden1/4delta30(me) contendo uma deleção de 30 nucleótidos (delta30) numa secção da região não traduzida a 3¿ do genoma da dengue de tipo 4, em que a referida deleção de 30 nucleótidos corresponde à estrutura em gancho de cabelo tl2 |
| CN102449172A (zh) | 2009-06-01 | 2012-05-09 | 伊维拉根公司 | 施用针对登革病毒的疫苗的组合物和方法 |
| WO2013188315A1 (en) * | 2012-06-10 | 2013-12-19 | Inviragen, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| SG11201401733VA (en) * | 2011-10-25 | 2014-09-26 | Florida Gulf Coast University | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
| MY168959A (en) * | 2012-07-24 | 2019-01-28 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
| TW201428101A (zh) * | 2012-11-08 | 2014-07-16 | Inviragen Inc | 登革熱病毒血清型４型之建構物的組成物、方法及用途 |
| WO2014093182A1 (en) | 2012-12-14 | 2014-06-19 | Inviragen, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| KR102389908B1 (ko) * | 2013-03-15 | 2022-04-26 | 다케다 백신즈 인코포레이티드 | 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법 |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| KR102611235B1 (ko) * | 2016-04-13 | 2023-12-08 | 다케다 백신즈 인코포레이티드 | 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법 |
| ES2908304T3 (es) * | 2018-09-05 | 2022-04-28 | Takeda Vaccines Inc | Dosis unitaria de vacuna contra el dengue y administración de la misma |
| US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
-
2017
- 2017-04-13 KR KR1020187032733A patent/KR102611235B1/ko active Active
- 2017-04-13 BR BR112018071087-3A patent/BR112018071087A2/pt unknown
- 2017-04-13 CN CN202510170711.1A patent/CN120392993A/zh active Pending
- 2017-04-13 CN CN201780028507.XA patent/CN109069615B/zh active Active
- 2017-04-13 SG SG10201913383RA patent/SG10201913383RA/en unknown
- 2017-04-13 PH PH1/2018/502175A patent/PH12018502175B1/en unknown
- 2017-04-13 CA CA3020484A patent/CA3020484A1/en active Pending
- 2017-04-13 JP JP2018553428A patent/JP2019511533A/ja active Pending
- 2017-04-13 SG SG11201808906RA patent/SG11201808906RA/en unknown
- 2017-04-13 US US16/093,385 patent/US11007261B2/en active Active
- 2017-04-13 MX MX2018012459A patent/MX2018012459A/es unknown
- 2017-04-13 EP EP17721858.3A patent/EP3442571A1/en active Pending
- 2017-04-13 AU AU2017250696A patent/AU2017250696A1/en not_active Abandoned
- 2017-04-13 MY MYPI2018001735A patent/MY192806A/en unknown
- 2017-04-13 WO PCT/IB2017/052160 patent/WO2017179017A1/en not_active Ceased
-
2018
- 2018-10-24 CO CONC2018/0011355A patent/CO2018011355A2/es unknown
- 2018-11-19 AU AU2018267542A patent/AU2018267542B2/en active Active
-
2021
- 2021-04-13 US US17/229,109 patent/US20210236620A1/en not_active Abandoned
-
2022
- 2022-04-20 JP JP2022069423A patent/JP2022089964A/ja active Pending
-
2024
- 2024-03-21 JP JP2024044760A patent/JP2024071463A/ja not_active Withdrawn
- 2024-08-30 US US18/821,030 patent/US20250235522A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511533A5 (enExample) | ||
| Pletnev et al. | Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus | |
| Khetarpal et al. | Dengue fever: causes, complications, and vaccine strategies | |
| Pugachev et al. | New developments in flavivirus vaccines with special attention to yellow fever | |
| EP1991709B1 (en) | Pseudoinfectious flavivirus and uses thereof | |
| Lanciotti et al. | Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East | |
| JP4993301B2 (ja) | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン | |
| ES2677348T3 (es) | Un virus del dengue quimérico recombinante rDEN3/4delta 30(ME), rDEN2/4delta30(ME) o rDEN1/4delta30(ME) que contiene una deleción de 30 nucleótidos (delta30) en una sección de la región no traducida en 3' del genoma del dengue de tipo 4, en donde dicha deleción de 30 nucleótidos se corresponde con la estructura tallo-bucle de TL2 | |
| Monath et al. | West Nile virus vaccine. | |
| US9499588B2 (en) | Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereof | |
| Huang et al. | Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus | |
| AU2017250696A1 (en) | Compositions and methods of vaccination against dengue virus in children and young adults | |
| JP2016513970A5 (enExample) | ||
| JP5469336B2 (ja) | 組換えフラビウイルスワクチン | |
| JP2019511221A (ja) | 弱毒化された生ジカウイルスワクチン | |
| WO2018129160A1 (en) | Live attenuated flavivirus vaccines and methods of using and making same | |
| ES2444691T3 (es) | Proteína de la cápside del virus del Dengue que induce una respuesta protectora y su composición farmacéutica | |
| ES2637629T3 (es) | Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo | |
| Pugachev et al. | Chimeric vaccines against Japanese encephalitis, dengue, and West Nile | |
| Simasathein et al. | Dengue vaccine | |
| Pulmanausahakul et al. | The development of flavivirus vaccines | |
| AU2019203166A1 (en) | Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus | |
| HK1120431A (en) | Recombinant flavivirus vaccines |